The potential hepatoprotective effects of GLP-1 RAs for the treatment of NAFLD or NASH include a significant improvement in hepatic fat content as assessed by imaging techniques (for all GLP-1 RAs), alongside histological resolution of NASH without worsening or improvement of histological fibrosis (data available only for liraglutide and semaglutide) [51] (Table 1). The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.